Relay Therapeutics, Inc.
RLAY
$3.26
$0.061.88%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.01M | 10.01M | 35.21M | 35.33M | 25.55M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.01M | 10.01M | 35.21M | 35.33M | 25.55M |
| Cost of Revenue | 315.44M | 324.88M | 329.75M | 325.96M | 326.39M |
| Gross Profit | -305.43M | -314.87M | -294.55M | -290.64M | -300.84M |
| SG&A Expenses | 80.24M | 80.09M | 78.82M | 78.80M | 78.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 395.68M | 404.96M | 408.57M | 404.76M | 404.97M |
| Operating Income | -385.67M | -394.96M | -373.37M | -369.44M | -379.42M |
| Income Before Tax | -337.71M | -345.20M | -322.83M | -329.12M | -341.97M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -337.71 | -345.20 | -322.83 | -329.12 | -341.97 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -337.71M | -345.20M | -322.83M | -329.12M | -341.97M |
| EBIT | -385.67M | -394.96M | -373.37M | -369.44M | -379.42M |
| EBITDA | -380.21M | -389.45M | -367.87M | -363.97M | -374.15M |
| EPS Basic | -2.40 | -2.61 | -2.52 | -2.64 | -2.79 |
| Normalized Basic EPS | -1.56 | -1.71 | -1.66 | -1.69 | -1.78 |
| EPS Diluted | -2.40 | -2.61 | -2.52 | -2.64 | -2.79 |
| Normalized Diluted EPS | -1.56 | -1.71 | -1.66 | -1.69 | -1.78 |
| Average Basic Shares Outstanding | 571.23M | 528.65M | 510.65M | 499.51M | 489.99M |
| Average Diluted Shares Outstanding | 571.23M | 528.65M | 510.65M | 499.51M | 489.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |